HealthMore in Health→
FDA Clears Axsome’s Auvelity for Alzheimer’s Agitation, Marking a Notable New Regulatory Step
Key Takeaways
- Endpoints reports that the FDA approved Axsome Therapeutics’ Auvelity for Alzheimer’s agitation.
- Axsome says up to 76% of Alzheimer’s patients experience agitation.
- The supplied text characterizes agitation with symptoms including pacing and restlessness.
DE
DT Editorial Team··via endpoints.news